Drug and Therapeutics Bulletin 2001;39:30-32; doi:10.1136/dtb.2001.39430
Copyright © 2001 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Can {blacktriangledown}verteporfin help in macular degeneration?

Relevant BNF section: 11.8.2

Age-related macular degeneration (AMD), a disorder affecting older people, is the commonest cause of severe visual impairment in the UK.1 It involves degeneration of the central retina (the macula) that results in diminished capacity for detailed visual tasks, such as reading, writing and recognising faces. For most people with AMD there is no effective treatment. &#9660Verteporfin* (Visudyne - Novartis Ophthalmics) was licensed last year for use in conjunction with laser activation (photodynamic therapy) for the treatment of "age-related macular degeneration in patients with predominantly classic subfoveal neovascularisation".3 Here, we review the place of this treatment.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2001 BMJ Publishing Group Ltd.